# EDGAR Filing Document

**Accession Number:** 0001642380
**File Stem:** 0001493152-26-029078
**Filing Date:** 2026-6
**Character Count:** 12649
**Document Hash:** 52a93d89765ef73a0bb05efcf807e9dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-029078.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001493152-26-029078

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Insight Molecular Diagnostics Inc.
- **CENTRAL INDEX KEY:** 0001642380
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271041563
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37648
- **FILM NUMBER:** 261098314

**BUSINESS ADDRESS:**
- **STREET 1:** 2 INTERNATIONAL PLAZA DR., SUITE 510
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37217
- **BUSINESS PHONE:** 949-409-7600

**MAIL ADDRESS:**
- **STREET 1:** 2 INTERNATIONAL PLAZA DR., SUITE 510
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oncocyte Corp
- **DATE OF NAME CHANGE:** 20210920

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OncoCyte Corp
- **DATE OF NAME CHANGE:** 20200213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oncocyte Corp
- **DATE OF NAME CHANGE:** 20200205

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 11, 2026**

**Insight Molecular Diagnostics Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **California** | **1-37648** | **27-1041563** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File No.) | (IRS Employer<br> Identification No.) |

---

**2 International Plaza Dr., Suite 510**

**Nashville, Tennessee 37217**

(Address of principal executive offices) (Zip code)

**(615) 255-8880**

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, no par value | IMDX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As reported below under Item 5.07 of this report, Insight Molecular Diagnostics Inc. (the "Company") held its 2026 Annual Meeting of Shareholders (the "Annual Meeting") on June 11, 2026, at which the Company's shareholders approved an amendment to the Company's Amended and Restated 2018 Equity Incentive Plan (as previously amended, the "Incentive Plan") to provide for an additional 1,750,000 shares of the Company's common stock to be available for the issuance of equity awards thereunder, such that the total number of shares of common stock authorized for issuance under the Incentive Plan is 5,550,000 shares of common stock.

For more information about the Incentive Plan, see the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting, which was originally filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"), the relevant portions of which are incorporated herein by reference. The foregoing description of the amendment to the Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the amendment to the Incentive Plan, a copy of which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

**General**

The Annual Meeting was held on June 11, 2026, virtually via live webcast at *https://edge.media-server.com/mmc/p/k94peovi*. Present at the Annual Meeting virtually or by proxy were holders of 23,954,212 shares of common stock of the Company, which represented 74.19% of the voting power of all shares of common stock of the Company as of April 27, 2026, the record date for the Annual Meeting.

**Proposals**

The shareholders of the Company voted on the following proposals at the Annual Meeting, as more fully described in the Proxy Statement:

&nbsp;&nbsp;&nbsp;&nbsp;1. To
 elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor
 has been elected and qualified, or until his earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and
 Louis E. Silverman;

&nbsp;&nbsp;&nbsp;&nbsp;2. To
 ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending
 December 31, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;3. To
 approve, on a non-binding advisory basis, the Company's named executive officer compensation for the year ended December 31,
 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;4. To
 approve an amendment to the Incentive Plan to increase the total number of shares of the Company's common stock authorized
 for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares.

**Voting Results**

The final voting results for each of these proposals at the Annual Meeting are detailed below.

**1. Election of Directors**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| <br>**Director Nominee** |<br>**For** | **Against** | **Abstained** | **Broker Non-Votes** |
| Joshua Riggs | 19239253 | 2420 | 3820 | 4708719 |
| Andrew Arno | 19100993 | 140445 | 4056 | 4708719 |
| Andrew J. Last | 19237621 | 3938 | 3935 | 4708719 |
| Louis E. Silverman | 19224148 | 17290 | 4056 | 4708719 |

---

Based on the votes set forth above, each director nominee was duly elected to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal.

**2. Ratification of Appointment of Accounting Firm**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 23949191 | 2420 | 2601 | 0 |

---

Based on the votes set forth above, the shareholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2026.

**3. Say On Pay Proposal**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 19199697 | 26126 | 19679 | 4708719 |

---

Based on the votes set forth above, the shareholders approved, on a non-binding advisory basis, the Company's named executive officer compensation for the year ended December 31, 2025.

**4. Approval of Amendment to Incentive Plan**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 19117865 | 122829 | 4799 | 4708719 |

---

Based on the votes set forth above, the shareholders approved the amendment to the Incentive Plan to increase the total number of shares of the Company's common stock authorized for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| **10.1#** | [Second Amendment to the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan](ex10-1.htm) |
| **104** | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

# The referenced exhibit is a management contract, compensatory plan or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INSIGHT MOLECULAR DIAGNOSTICS INC.** | **INSIGHT MOLECULAR DIAGNOSTICS INC.** |
| Date: June 17, 2026 | By: | */s/ Peter Hong* |
|  | Name: | Peter Hong |
|  | Title: | Vice President, General Counsel |

---

## Exhibit 10.1

**Exhibit 10.1**

**SECOND AMENDMENT**

**TO THE**

**INSIGHT MOLECULAR DIAGNOSTICS INC.**

**AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN**

This SECOND AMENDMENT TO THE INSIGHT MOLECULAR DIAGNOSTICS INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this "***Amendment***"), effective as of June 11, 2026, is made and entered into by Insight Molecular Diagnostics Inc., a California corporation (the "***Company***"). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan (as amended, the "***Plan***").

**<u>RECITALS</u>**

**WHEREAS**, Section 13.1 of the Plan provides that the Board of Directors of the Company (the "***Board***") may amend the Plan at any time and from time to time;

**WHEREAS**, the Board desires to amend the Plan to increase the aggregate number of shares of Common Stock that may be issued under the Plan as set forth in Section 4.1 of the Plan by an additional 1,750,000 shares of Common Stock; and

**WHEREAS**, the Board intends to submit this Amendment to the Company's shareholders for their approval.

**NOW, THEREFORE**, in accordance with Section 13.1 of the Plan, the Company hereby amends the Plan as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 4.1 of the Plan is hereby amended by deleting said section in its entirety and substituting in lieu thereof the following new Section 4.1:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 Subject to adjustment in accordance with Section 11, a total of 5,550,000 shares of Common Stock shall be available for the grant of Awards under the Plan, of which 100% may be delivered pursuant to Incentive Stock Options. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. This Amendment shall be effective on the date first set forth above. In the event shareholder approval of this Amendment is not obtained within twelve (12) months of the date the Board approved this Amendment, the additional shares added to the Plan pursuant to this Amendment shall not be available for grant as Incentive Stock Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions thereof.